Short answer
CorMedix Inc. (CRMD) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $102M (up 156.5% year over year) with net income of $26M.
Q2 2026 key financials · XBRL
- Revenue
- $102M
- +156.5% YoY · −20.0% QoQ
- Net income
- $26M
- +31.1% YoY · −32.7% QoQ
- Operating margin
- 42.1%
- Gross margin
- 75.7%
- EPS (diluted)
- $0.29
- +3.6% YoY · −32.6% QoQ
Source: XBRL data from the CorMedix Inc. (CRMD) Q2 2026 10-Q on SEC EDGAR. USD.
CorMedix Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue and grant income $101.9M, up 157% YoY from $39.7M
- Gross margin 75.6% vs 95.3% YoY; operating margin 42.1% vs 49.2%
- Best performer DefenCath sales $66.1M vs $39.7M; Melinta Portfolio $28.2M
- Cash, equivalents and short-term investments $256.7M vs $148.5M at December 31, 2025
- Operating cash flow $128.6M vs $49.7M; financing used $19.2M
- DefenCath post-TDAPA transition expected to reduce second-half 2026 net sales; 2027 payment could increase meaningfully
Risk Factors
- Risk-factor section not provided; no quarter-specific risk changes identifiable
- Share repurchase authorization: up to $75 million through December 31, 2027
- Repurchase liquidity use: $6.4 million remaining after 814,281 shares purchased at $7.85
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CorMedix Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.